EFG Asset Management Americas Corp. Has $240,000 Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

EFG Asset Management Americas Corp. cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 15.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,496 shares of the biopharmaceutical company’s stock after selling 1,186 shares during the quarter. EFG Asset Management Americas Corp.’s holdings in Halozyme Therapeutics were worth $240,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. US Bancorp DE raised its stake in shares of Halozyme Therapeutics by 43.8% in the first quarter. US Bancorp DE now owns 12,663 shares of the biopharmaceutical company’s stock valued at $506,000 after purchasing an additional 3,859 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of Halozyme Therapeutics by 7.3% in the first quarter. HighTower Advisors LLC now owns 11,952 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 812 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Halozyme Therapeutics by 31.9% in the first quarter. PNC Financial Services Group Inc. now owns 16,826 shares of the biopharmaceutical company’s stock valued at $671,000 after purchasing an additional 4,066 shares in the last quarter. Natixis Advisors L.P. raised its stake in shares of Halozyme Therapeutics by 14.9% in the first quarter. Natixis Advisors L.P. now owns 30,219 shares of the biopharmaceutical company’s stock valued at $1,205,000 after purchasing an additional 3,928 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Halozyme Therapeutics by 10.5% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 51,597 shares of the biopharmaceutical company’s stock valued at $2,058,000 after purchasing an additional 4,920 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the transaction, the senior vice president now owns 156,558 shares of the company’s stock, valued at $6,519,075.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have sold 30,000 shares of company stock valued at $1,196,800. 2.70% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $38.64 on Monday. The business’s 50-day simple moving average is $39.56 and its 200 day simple moving average is $37.77. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of 18.31, a P/E/G ratio of 0.45 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The company had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on HALO. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. Morgan Stanley lowered their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 26th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, April 17th. JMP Securities reiterated a “market outperform” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. Finally, StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.29.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.